Today: June 25, 2017, 5:31 pm
  
Health

AMPS LLC announces the release of version 3 of TrialPerfect, its back-end database system

AMPS LLC is pleased to announce the release of TrialPerfect version 3.0.
AMPS LLC announces the release of version 3 of TrialPerfect, its back-end database system
PR-Inside.com: 2017-06-15 16:37:05
TrialPerfect is the back-end database system offered by AMPS that complements its well-known product CalECG the AMPS on-screen measurement application, thus offering a complete solution for ECG measurements and related applications in clinical trials.

The main advantage of CalECG/TrialPerfect is to provide a professional, secure and user-friendly client/server environment for the storage, analysis, interpretation, validation and review of ECG traces in the context of clinical trials. TrialPerfect is “21 CFR Part 11” compliant.

TrialPerfect v 3.0 offers a user-friendly Web interface whereby the management of annotations is completely handled by the back-end process and is traceable through a complete audit trail. The application supports all ECG file formats supported by CalECG, such as Mortara E-Scribe XML, Muse XML, HL7 XML and many others. The system also allows for fully configurable intra-reader and inter-reader variability assessment for quality purpose.

The new version of TrialPerfect offers the following major enhancements:

• Increased safety for completed studies: it now requires two people to authorize the reopening of a study

• Affords Project Managers the ability to generate customized PDF report

• Interpretative statements are grouped in physiologic categories

• An added ability to highlight annotation caliper with keyboard keys in CalECG

• It is now possible to highlight abnormal annotation values in CalECG

• Ability to annotate TpTe, QTP, JT, JTP and Pdur measurements

• Enhanced linkage to FAT-QT, with the possibility to use QRS & PR intervals for classification

• Possibility to apply the FDA open-source algorithm ECGLib for the measurement of JTp/TpTe intervals

Fabio Badilini, PhD, FACC, Chief Scientist and AMPS founder commented: “These last few months have been very exciting as we made major steps forward in several of our products, and developed new ones to answer the needs of the market, which led to the set of announcements made today. He also added: “I am particularly proud both for the result we achieved and of the AMPS team of engineers that helped in achieving such a major leap forward for our customers”.

About AMPS LLC: Based in New York (NY), AMPS LLC is a dynamic software company providing cutting-edge software solutions for key applications like Quantitative ECG Analysis and Blood Pressure Monitoring that are critical measurements for Clinical Research Organizations and Pharmaceutical companies. AMPS LLC is well known for the support it has been extending to the FDA in establishing the HL7 XML ECG standards, and for providing its famous AMPS XMLFDA Viewer tool to the FDA.

The company’s website is www.amps-llc.com. For more information, please contact:

AMPS, LLC

418 Central Park West

New York, NY, 10025

For pricing propositions: marketing@amps-llc.com

For technical questions: support@amps-llc.com

Press Information
AMPS LLC
418 Central Park West

Daniel Bovio
VP Marketing & Sales
2127494076
email
www.amps-llc.com


# 443 Words
Related Articles
More From The Author
AMPS LLC releases version 2 of FAT-QT, [..]
AMPS is proud to announce the official release of version 2 of FAT-QT (Fully Automatic Thorough-QT), which brings together the [..]
AMPS LLC releases version 4 of the [..]
AMPS is pleased to announce the release of version 4 of CalECG, our popular application for on-screen measurement of ECG [..]
 
More From Health
PromarkerD can predict Diabetic Kidney Disease better [..]
- PromarkerD predicted 86% of disease-free patients who went on to develop chronic kidney disease within four years - Largest [..]
Human Heart Tissue Grown from Stem Cells [..]
SINGAPORE, June 8, 2017 - (ACN Newswire) - Researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have [..]
Cannabidiol (CBD) Oil Rated as "A Game [..]
While there is still a lot of research to be done, we have already gotten some pretty promising results about [..]
Global and Chinese 5-Aminosalicylic acid Industry Market [..]
HTF Market Intelligence released a new research report of 150 pages on title 'Global and Chinese 5-Aminosalicylic acid (CAS 89-57-6) [..]
New Silkroutes Group to Acquire Dental Businesses [..]
Expected to be completed by 31 July 2017, acquisitions will bolster capabilities of NSG's 51%-owned healthcare practice group, [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.